English
简体中文
Total: £ 56.28
Published Date: 2026-03-27 | Pages: 133 | Tables: 130 | Pharma & Healthcare
The global Oral Antiparkinsonian Drugs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Oral Antiparkinsonian Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Oral antiparkinsonian drugs are medications taken by mouth to manage the symptoms of Parkinson's disease, a neurodegenerative disorder characterized by tremors, stiffness, slow movement, and balance problems. These drugs aim to restore the balance of dopamine and other neurotransmitters in the brain, thereby improving motor function and quality of life for patients. Common oral antiparkinsonian medications include levodopa (often combined with carbidopa to enhance its effectiveness), dopamine agonists (such as pramipexole and ropinirole), MAO-B inhibitors (like selegiline and rasagiline), and anticholinergics (such as benztropine). Each drug works differently, and treatment is typically tailored to the individual's specific symptoms and disease progression, often involving a combination of medications to achieve optimal control of Parkinson's symptoms.
The North American market for Oral Antiparkinsonian Drugs is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Oral Antiparkinsonian Drugs is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Oral Antiparkinsonian Drugs include AbbVie, Merck, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharma, Supernus Pharmaceuticals, Bausch Health, Newron Pharmaceuticals, Teva Pharmaceutica, Glenmark Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Oral Antiparkinsonian Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oral Antiparkinsonian Drugs. The Oral Antiparkinsonian Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Oral Antiparkinsonian Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Oral Antiparkinsonian Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AbbVie
Merck
Boehringer Ingelheim
GlaxoSmithKline
Novartis Pharma
Supernus Pharmaceuticals
Bausch Health
Newron Pharmaceuticals
Teva Pharmaceutica
Glenmark Pharmaceuticals
Orion Pharma
Neurocrine Biosciences
Kyowa Kirin
UCB
Desitin Arzneimittel
Amneal Pharmaceuticals
Organon Pharma
F.Hoffmann-La Roche
Lundbeck
Stada
Segment by Type
L-Dopa Formulations
Dopamine Agonists
Mao-B Inhibitors
COMT Inhibitors
by Application
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Oral Antiparkinsonian Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Oral Antiparkinsonian Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Oral Antiparkinsonian Drugs Market Overview
1.1 Product Definition
1.2 Oral Antiparkinsonian Drugs by Type
1.2.1 Global Oral Antiparkinsonian Drugs Market Value by Type: 2025 vs 2032
1.2.2 L-Dopa Formulations
1.2.3 Dopamine Agonists
1.2.4 Mao-B Inhibitors
1.2.5 COMT Inhibitors
1.3 Oral Antiparkinsonian Drugs by Application
1.3.1 Global Oral Antiparkinsonian Drugs Market Value by Application: 2025 vs 2032
1.3.2 Under 40 Years Old
1.3.3 40-65 Years Old
1.3.4 Above 65 Years Old
1.4 Global Oral Antiparkinsonian Drugs Market Size Estimates and Forecasts
1.4.1 Global Oral Antiparkinsonian Drugs Revenue 2021–2032
1.4.2 Global Oral Antiparkinsonian Drugs Sales 2021–2032
1.4.3 Global Oral Antiparkinsonian Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Oral Antiparkinsonian Drugs Market Competition by Manufacturers
2.1 Global Oral Antiparkinsonian Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Oral Antiparkinsonian Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Oral Antiparkinsonian Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Oral Antiparkinsonian Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Oral Antiparkinsonian Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Oral Antiparkinsonian Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Oral Antiparkinsonian Drugs, Date of Entry into the Industry
2.8 Global Oral Antiparkinsonian Drugs Market Competitive Situation and Trends
2.8.1 Global Oral Antiparkinsonian Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Oral Antiparkinsonian Drugs Players Market Share by Revenue
2.8.3 Global Oral Antiparkinsonian Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oral Antiparkinsonian Drugs Market Scenario by Region
3.1 Global Oral Antiparkinsonian Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Oral Antiparkinsonian Drugs Sales by Region: 2021–2032
3.2.1 Global Oral Antiparkinsonian Drugs Sales by Region: 2021–2026
3.2.2 Global Oral Antiparkinsonian Drugs Sales by Region: 2027–2032
3.3 Global Oral Antiparkinsonian Drugs Revenue by Region: 2021–2032
3.3.1 Global Oral Antiparkinsonian Drugs Revenue by Region: 2021–2026
3.3.2 Global Oral Antiparkinsonian Drugs Revenue by Region: 2027–2032
3.4 North America Oral Antiparkinsonian Drugs Market Facts & Figures by Country
3.4.1 North America Oral Antiparkinsonian Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Oral Antiparkinsonian Drugs Sales by Country (2021–2032)
3.4.3 North America Oral Antiparkinsonian Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oral Antiparkinsonian Drugs Market Facts & Figures by Country
3.5.1 Europe Oral Antiparkinsonian Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Oral Antiparkinsonian Drugs Sales by Country (2021–2032)
3.5.3 Europe Oral Antiparkinsonian Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Antiparkinsonian Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Oral Antiparkinsonian Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Oral Antiparkinsonian Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Oral Antiparkinsonian Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oral Antiparkinsonian Drugs Market Facts & Figures by Country
3.7.1 Latin America Oral Antiparkinsonian Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Oral Antiparkinsonian Drugs Sales by Country (2021–2032)
3.7.3 Latin America Oral Antiparkinsonian Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Oral Antiparkinsonian Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Antiparkinsonian Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Oral Antiparkinsonian Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Oral Antiparkinsonian Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral Antiparkinsonian Drugs Sales by Type (2021–2032)
4.1.1 Global Oral Antiparkinsonian Drugs Sales by Type (2021–2026)
4.1.2 Global Oral Antiparkinsonian Drugs Sales by Type (2027–2032)
4.1.3 Global Oral Antiparkinsonian Drugs Sales Market Share by Type (2021–2032)
4.2 Global Oral Antiparkinsonian Drugs Revenue by Type (2021–2032)
4.2.1 Global Oral Antiparkinsonian Drugs Revenue by Type (2021–2026)
4.2.2 Global Oral Antiparkinsonian Drugs Revenue by Type (2027–2032)
4.2.3 Global Oral Antiparkinsonian Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Oral Antiparkinsonian Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Oral Antiparkinsonian Drugs Sales by Application (2021–2032)
5.1.1 Global Oral Antiparkinsonian Drugs Sales by Application (2021–2026)
5.1.2 Global Oral Antiparkinsonian Drugs Sales by Application (2027–2032)
5.1.3 Global Oral Antiparkinsonian Drugs Sales Market Share by Application (2021–2032)
5.2 Global Oral Antiparkinsonian Drugs Revenue by Application (2021–2032)
5.2.1 Global Oral Antiparkinsonian Drugs Revenue by Application (2021–2026)
5.2.2 Global Oral Antiparkinsonian Drugs Revenue by Application (2027–2032)
5.2.3 Global Oral Antiparkinsonian Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Oral Antiparkinsonian Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Company Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AbbVie Oral Antiparkinsonian Drugs Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Merck Oral Antiparkinsonian Drugs Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Company Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Boehringer Ingelheim Oral Antiparkinsonian Drugs Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Company Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 GlaxoSmithKline Oral Antiparkinsonian Drugs Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Novartis Pharma
6.5.1 Novartis Pharma Company Information
6.5.2 Novartis Pharma Description and Business Overview
6.5.3 Novartis Pharma Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Novartis Pharma Oral Antiparkinsonian Drugs Product Portfolio
6.5.5 Novartis Pharma Recent Developments/Updates
6.6 Supernus Pharmaceuticals
6.6.1 Supernus Pharmaceuticals Company Information
6.6.2 Supernus Pharmaceuticals Description and Business Overview
6.6.3 Supernus Pharmaceuticals Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Supernus Pharmaceuticals Oral Antiparkinsonian Drugs Product Portfolio
6.6.5 Supernus Pharmaceuticals Recent Developments/Updates
6.7 Bausch Health
6.7.1 Bausch Health Company Information
6.7.2 Bausch Health Description and Business Overview
6.7.3 Bausch Health Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Bausch Health Oral Antiparkinsonian Drugs Product Portfolio
6.7.5 Bausch Health Recent Developments/Updates
6.8 Newron Pharmaceuticals
6.8.1 Newron Pharmaceuticals Company Information
6.8.2 Newron Pharmaceuticals Description and Business Overview
6.8.3 Newron Pharmaceuticals Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Newron Pharmaceuticals Oral Antiparkinsonian Drugs Product Portfolio
6.8.5 Newron Pharmaceuticals Recent Developments/Updates
6.9 Teva Pharmaceutica
6.9.1 Teva Pharmaceutica Company Information
6.9.2 Teva Pharmaceutica Description and Business Overview
6.9.3 Teva Pharmaceutica Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Teva Pharmaceutica Oral Antiparkinsonian Drugs Product Portfolio
6.9.5 Teva Pharmaceutica Recent Developments/Updates
6.10 Glenmark Pharmaceuticals
6.10.1 Glenmark Pharmaceuticals Company Information
6.10.2 Glenmark Pharmaceuticals Description and Business Overview
6.10.3 Glenmark Pharmaceuticals Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Glenmark Pharmaceuticals Oral Antiparkinsonian Drugs Product Portfolio
6.10.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.11 Orion Pharma
6.11.1 Orion Pharma Company Information
6.11.2 Orion Pharma Description and Business Overview
6.11.3 Orion Pharma Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Orion Pharma Oral Antiparkinsonian Drugs Product Portfolio
6.11.5 Orion Pharma Recent Developments/Updates
6.12 Neurocrine Biosciences
6.12.1 Neurocrine Biosciences Company Information
6.12.2 Neurocrine Biosciences Description and Business Overview
6.12.3 Neurocrine Biosciences Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Neurocrine Biosciences Oral Antiparkinsonian Drugs Product Portfolio
6.12.5 Neurocrine Biosciences Recent Developments/Updates
6.13 Kyowa Kirin
6.13.1 Kyowa Kirin Company Information
6.13.2 Kyowa Kirin Description and Business Overview
6.13.3 Kyowa Kirin Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Kyowa Kirin Oral Antiparkinsonian Drugs Product Portfolio
6.13.5 Kyowa Kirin Recent Developments/Updates
6.14 UCB
6.14.1 UCB Company Information
6.14.2 UCB Description and Business Overview
6.14.3 UCB Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 UCB Oral Antiparkinsonian Drugs Product Portfolio
6.14.5 UCB Recent Developments/Updates
6.15 Desitin Arzneimittel
6.15.1 Desitin Arzneimittel Company Information
6.15.2 Desitin Arzneimittel Description and Business Overview
6.15.3 Desitin Arzneimittel Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Desitin Arzneimittel Oral Antiparkinsonian Drugs Product Portfolio
6.15.5 Desitin Arzneimittel Recent Developments/Updates
6.16 Amneal Pharmaceuticals
6.16.1 Amneal Pharmaceuticals Company Information
6.16.2 Amneal Pharmaceuticals Description and Business Overview
6.16.3 Amneal Pharmaceuticals Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Amneal Pharmaceuticals Oral Antiparkinsonian Drugs Product Portfolio
6.16.5 Amneal Pharmaceuticals Recent Developments/Updates
6.17 Organon Pharma
6.17.1 Organon Pharma Company Information
6.17.2 Organon Pharma Description and Business Overview
6.17.3 Organon Pharma Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Organon Pharma Oral Antiparkinsonian Drugs Product Portfolio
6.17.5 Organon Pharma Recent Developments/Updates
6.18 F.Hoffmann-La Roche
6.18.1 F.Hoffmann-La Roche Company Information
6.18.2 F.Hoffmann-La Roche Description and Business Overview
6.18.3 F.Hoffmann-La Roche Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 F.Hoffmann-La Roche Oral Antiparkinsonian Drugs Product Portfolio
6.18.5 F.Hoffmann-La Roche Recent Developments/Updates
6.19 Lundbeck
6.19.1 Lundbeck Company Information
6.19.2 Lundbeck Description and Business Overview
6.19.3 Lundbeck Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Lundbeck Oral Antiparkinsonian Drugs Product Portfolio
6.19.5 Lundbeck Recent Developments/Updates
6.20 Stada
6.20.1 Stada Company Information
6.20.2 Stada Description and Business Overview
6.20.3 Stada Oral Antiparkinsonian Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 Stada Oral Antiparkinsonian Drugs Product Portfolio
6.20.5 Stada Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Antiparkinsonian Drugs Industry Chain Analysis
7.2 Oral Antiparkinsonian Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Antiparkinsonian Drugs Production Mode & Process Analysis
7.4 Oral Antiparkinsonian Drugs Sales and Marketing
7.4.1 Oral Antiparkinsonian Drugs Sales Channels
7.4.2 Oral Antiparkinsonian Drugs Distributors
7.5 Oral Antiparkinsonian Drugs Customer Analysis
8 Oral Antiparkinsonian Drugs Market Dynamics
8.1 Oral Antiparkinsonian Drugs Industry Trends
8.2 Oral Antiparkinsonian Drugs Market Drivers
8.3 Oral Antiparkinsonian Drugs Market Challenges
8.4 Oral Antiparkinsonian Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Oral Antiparkinsonian Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Oral Antiparkinsonian Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Oral Antiparkinsonian Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Oral Antiparkinsonian Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Oral Antiparkinsonian Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Oral Antiparkinsonian Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Oral Antiparkinsonian Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Oral Antiparkinsonian Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Oral Antiparkinsonian Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Oral Antiparkinsonian Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Oral Antiparkinsonian Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Oral Antiparkinsonian Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oral Antiparkinsonian Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Oral Antiparkinsonian Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oral Antiparkinsonian Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Oral Antiparkinsonian Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Oral Antiparkinsonian Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Oral Antiparkinsonian Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Oral Antiparkinsonian Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Oral Antiparkinsonian Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Oral Antiparkinsonian Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Oral Antiparkinsonian Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Oral Antiparkinsonian Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Oral Antiparkinsonian Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Oral Antiparkinsonian Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Oral Antiparkinsonian Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Oral Antiparkinsonian Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Oral Antiparkinsonian Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Oral Antiparkinsonian Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Oral Antiparkinsonian Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Oral Antiparkinsonian Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Oral Antiparkinsonian Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Oral Antiparkinsonian Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Oral Antiparkinsonian Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Oral Antiparkinsonian Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Oral Antiparkinsonian Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Oral Antiparkinsonian Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Oral Antiparkinsonian Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Oral Antiparkinsonian Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Oral Antiparkinsonian Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Oral Antiparkinsonian Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Oral Antiparkinsonian Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Oral Antiparkinsonian Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Oral Antiparkinsonian Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Oral Antiparkinsonian Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Oral Antiparkinsonian Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Oral Antiparkinsonian Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Oral Antiparkinsonian Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Oral Antiparkinsonian Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Oral Antiparkinsonian Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Oral Antiparkinsonian Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Oral Antiparkinsonian Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Oral Antiparkinsonian Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Oral Antiparkinsonian Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Oral Antiparkinsonian Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Oral Antiparkinsonian Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Oral Antiparkinsonian Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Oral Antiparkinsonian Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Oral Antiparkinsonian Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Oral Antiparkinsonian Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Oral Antiparkinsonian Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Oral Antiparkinsonian Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Oral Antiparkinsonian Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Oral Antiparkinsonian Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Oral Antiparkinsonian Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Oral Antiparkinsonian Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Oral Antiparkinsonian Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Oral Antiparkinsonian Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. AbbVie Company Information
Table 71. AbbVie Description and Business Overview
Table 72. AbbVie Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. AbbVie Oral Antiparkinsonian Drugs Product
Table 74. AbbVie Recent Developments/Updates
Table 75. Merck Company Information
Table 76. Merck Description and Business Overview
Table 77. Merck Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Merck Oral Antiparkinsonian Drugs Product
Table 79. Merck Recent Developments/Updates
Table 80. Boehringer Ingelheim Company Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Boehringer Ingelheim Oral Antiparkinsonian Drugs Product
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. GlaxoSmithKline Company Information
Table 86. GlaxoSmithKline Description and Business Overview
Table 87. GlaxoSmithKline Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. GlaxoSmithKline Oral Antiparkinsonian Drugs Product
Table 89. GlaxoSmithKline Recent Developments/Updates
Table 90. Novartis Pharma Company Information
Table 91. Novartis Pharma Description and Business Overview
Table 92. Novartis Pharma Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Novartis Pharma Oral Antiparkinsonian Drugs Product
Table 94. Novartis Pharma Recent Developments/Updates
Table 95. Supernus Pharmaceuticals Company Information
Table 96. Supernus Pharmaceuticals Description and Business Overview
Table 97. Supernus Pharmaceuticals Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Supernus Pharmaceuticals Oral Antiparkinsonian Drugs Product
Table 99. Supernus Pharmaceuticals Recent Developments/Updates
Table 100. Bausch Health Company Information
Table 101. Bausch Health Description and Business Overview
Table 102. Bausch Health Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Bausch Health Oral Antiparkinsonian Drugs Product
Table 104. Bausch Health Recent Developments/Updates
Table 105. Newron Pharmaceuticals Company Information
Table 106. Newron Pharmaceuticals Description and Business Overview
Table 107. Newron Pharmaceuticals Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Newron Pharmaceuticals Oral Antiparkinsonian Drugs Product
Table 109. Newron Pharmaceuticals Recent Developments/Updates
Table 110. Teva Pharmaceutica Company Information
Table 111. Teva Pharmaceutica Description and Business Overview
Table 112. Teva Pharmaceutica Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Teva Pharmaceutica Oral Antiparkinsonian Drugs Product
Table 114. Teva Pharmaceutica Recent Developments/Updates
Table 115. Glenmark Pharmaceuticals Company Information
Table 116. Glenmark Pharmaceuticals Description and Business Overview
Table 117. Glenmark Pharmaceuticals Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Glenmark Pharmaceuticals Oral Antiparkinsonian Drugs Product
Table 119. Glenmark Pharmaceuticals Recent Developments/Updates
Table 120. Orion Pharma Company Information
Table 121. Orion Pharma Description and Business Overview
Table 122. Orion Pharma Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Orion Pharma Oral Antiparkinsonian Drugs Product
Table 124. Orion Pharma Recent Developments/Updates
Table 125. Neurocrine Biosciences Company Information
Table 126. Neurocrine Biosciences Description and Business Overview
Table 127. Neurocrine Biosciences Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Neurocrine Biosciences Oral Antiparkinsonian Drugs Product
Table 129. Neurocrine Biosciences Recent Developments/Updates
Table 130. Kyowa Kirin Company Information
Table 131. Kyowa Kirin Description and Business Overview
Table 132. Kyowa Kirin Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Kyowa Kirin Oral Antiparkinsonian Drugs Product
Table 134. Kyowa Kirin Recent Developments/Updates
Table 135. UCB Company Information
Table 136. UCB Description and Business Overview
Table 137. UCB Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. UCB Oral Antiparkinsonian Drugs Product
Table 139. UCB Recent Developments/Updates
Table 140. Desitin Arzneimittel Company Information
Table 141. Desitin Arzneimittel Description and Business Overview
Table 142. Desitin Arzneimittel Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Desitin Arzneimittel Oral Antiparkinsonian Drugs Product
Table 144. Desitin Arzneimittel Recent Developments/Updates
Table 145. Amneal Pharmaceuticals Company Information
Table 146. Amneal Pharmaceuticals Description and Business Overview
Table 147. Amneal Pharmaceuticals Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Amneal Pharmaceuticals Oral Antiparkinsonian Drugs Product
Table 149. Amneal Pharmaceuticals Recent Developments/Updates
Table 150. Organon Pharma Company Information
Table 151. Organon Pharma Description and Business Overview
Table 152. Organon Pharma Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. Organon Pharma Oral Antiparkinsonian Drugs Product
Table 154. Organon Pharma Recent Developments/Updates
Table 155. F.Hoffmann-La Roche Company Information
Table 156. F.Hoffmann-La Roche Description and Business Overview
Table 157. F.Hoffmann-La Roche Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 158. F.Hoffmann-La Roche Oral Antiparkinsonian Drugs Product
Table 159. F.Hoffmann-La Roche Recent Developments/Updates
Table 160. Lundbeck Company Information
Table 161. Lundbeck Description and Business Overview
Table 162. Lundbeck Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 163. Lundbeck Oral Antiparkinsonian Drugs Product
Table 164. Lundbeck Recent Developments/Updates
Table 165. Stada Company Information
Table 166. Stada Description and Business Overview
Table 167. Stada Oral Antiparkinsonian Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 168. Stada Oral Antiparkinsonian Drugs Product
Table 169. Stada Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Oral Antiparkinsonian Drugs Distributors List
Table 173. Oral Antiparkinsonian Drugs Customers List
Table 174. Oral Antiparkinsonian Drugs Market Trends
Table 175. Oral Antiparkinsonian Drugs Market Drivers
Table 176. Oral Antiparkinsonian Drugs Market Challenges
Table 177. Oral Antiparkinsonian Drugs Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
Table 181. Authors List of This Report
List of Figures
Figure 1. Product Picture of Oral Antiparkinsonian Drugs
Figure 2. Global Oral Antiparkinsonian Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Oral Antiparkinsonian Drugs Market Share by Type: 2025 & 2032
Figure 4. L-Dopa Formulations Product Picture
Figure 5. Dopamine Agonists Product Picture
Figure 6. Mao-B Inhibitors Product Picture
Figure 7. COMT Inhibitors Product Picture
Figure 8. Global Oral Antiparkinsonian Drugs Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Oral Antiparkinsonian Drugs Market Share by Application: 2025 & 2032
Figure 10. Under 40 Years Old
Figure 11. 40-65 Years Old
Figure 12. Above 65 Years Old
Figure 13. Global Oral Antiparkinsonian Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Oral Antiparkinsonian Drugs Market Size (US$ Million), 2021–2032
Figure 15. Global Oral Antiparkinsonian Drugs Sales (K Units), 2021–2032
Figure 16. Global Oral Antiparkinsonian Drugs Average Price (US$/Unit), 2021–2032
Figure 17. Oral Antiparkinsonian Drugs Report Years Considered
Figure 18. Oral Antiparkinsonian Drugs Sales Share by Manufacturers in 2025
Figure 19. Global Oral Antiparkinsonian Drugs Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Oral Antiparkinsonian Drugs Players: Market Share by Revenue in Oral Antiparkinsonian Drugs in 2025
Figure 21. Oral Antiparkinsonian Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Oral Antiparkinsonian Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Oral Antiparkinsonian Drugs Sales Market Share by Country (2021–2032)
Figure 24. North America Oral Antiparkinsonian Drugs Revenue Market Share by Country (2021–2032)
Figure 25. United States Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Oral Antiparkinsonian Drugs Sales Market Share by Country (2021–2032)
Figure 28. Europe Oral Antiparkinsonian Drugs Revenue Market Share by Country (2021–2032)
Figure 29. Germany Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Oral Antiparkinsonian Drugs Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Oral Antiparkinsonian Drugs Revenue Market Share by Region (2021–2032)
Figure 36. China Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Oral Antiparkinsonian Drugs Sales Market Share by Country (2021–2032)
Figure 44. Latin America Oral Antiparkinsonian Drugs Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Oral Antiparkinsonian Drugs Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Oral Antiparkinsonian Drugs Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Oral Antiparkinsonian Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Oral Antiparkinsonian Drugs by Type (2021–2032)
Figure 55. Global Revenue Market Share of Oral Antiparkinsonian Drugs by Type (2021–2032)
Figure 56. Global Oral Antiparkinsonian Drugs Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Oral Antiparkinsonian Drugs by Application (2021–2032)
Figure 58. Global Revenue Market Share of Oral Antiparkinsonian Drugs by Application (2021–2032)
Figure 59. Global Oral Antiparkinsonian Drugs Price (US$/Unit) by Application (2021–2032)
Figure 60. Oral Antiparkinsonian Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
